Biotech Company Valuation
Value a biotech or life sciences company using risk-adjusted NPV, pipeline analysis, and precedent transaction comps.
29 valuation methods · 43 industries · Results in under 10 minutes
Who this is for
Biotech founders preparing for Series B through IPO, corporate development teams evaluating licensing deals, and venture investors marking portfolio positions to market will find this the most relevant starting point.
Valuation methods we use
Pre-revenue biotech companies are most commonly valued using risk-adjusted net present value (rNPV), which discounts probability-weighted peak sales estimates back to today. Comparable transaction analysis on similar-stage asset acquisitions provides a market-based cross-check. This tool is informational only. Output is driven by your inputs and does not constitute a formal appraisal or certified valuation.
What drives value in Biotech
- Pipeline stage and probability of regulatory success by asset
- Breadth and enforceability of patent portfolio
- Platform versus single-asset risk profile
- Existing partnerships, co-development agreements, or licensing revenue
- Management team's track record of prior exits or approvals
- Cash runway relative to next value-creating milestone
Value your business in under 10 minutes
- 1.Upload your financial statements, or type the figures in.
- 2.Confirm the add-backs and the industry details the model asks for.
- 3.Get a valuation range, the methods behind it and a PDF memorandum.
Not ready yet? Try the calculator or see a sample report.
Typical metrics and inputs
Pipeline stage
The most advanced clinical or regulatory stage of the lead asset (Preclinical through NDA/BLA).
Peak sales estimate
Analyst or management projection of peak annual revenue if the asset reaches commercialization.
Probability of success (PoS)
Historical regulatory approval rates by indication and stage; used to risk-weight cash flows.
Cash runway
Months of operating expenses covered by current cash; short runway creates valuation pressure.
Burn rate
Monthly cash consumption; high burn relative to milestones signals dilution risk.
Example scenarios
Phase 2 oncology asset
A biotech with a Phase 2 oncology candidate targeting a $2 B peak-sales indication and a 25% PoS might generate an rNPV of $80–120 M on that single asset alone.
Platform technology with two IND filings
A platform company with two IND-stage programs and a strong management team might trade at a $40–70 M pre-money valuation in a Series B, reflecting pipeline optionality.
Further reading
How to Value a Dental Practice: Collections, EBITDA, and What DSOs Actually Pay
Dental practice valuation explained: the percentage-of-collections rule, when EBITDA multiples take over, what drives DSO offers, and a worked example for a $900K practice.
Is a Business Worth 3 Times Profit? When It Is 2x, When It Is 5x, and Which Profit Counts
Is a business worth 3 times profit? Often, if the profit is SDE. When 2x or 5x applies instead, which profit counts, and what diligence does to the price.
How Much Is a Business Worth With $500,000 in Sales? The Revenue Ladder From $100K to $3 Million
Revenue does not set a price, earnings do. See what businesses at $100K, $200K, $300K, $500K, $1M, $2M and $3M in sales are worth at 10%, 20% and 30% margins.
Frequently asked questions
How do you value a pre-revenue biotech?
The most common method is risk-adjusted NPV (rNPV): estimate peak sales, apply probability of approval, and discount future cash flows to present value.
What discount rate is used for biotech DCF?
Biotech-specific discount rates typically range from 15–30%, reflecting development risk and binary outcomes.
How much does a Phase 2 asset add to valuation?
Phase 2 assets in large indications can add $50–300 M in rNPV depending on the indication size, competitive landscape, and probability of success.
Does platform technology get valued separately?
Yes - platforms with optionality across multiple indications command a premium over single-asset companies, typically reflected in higher exit multiples.
Is this a certified appraisal?
No. Value Alpha provides AI-generated estimates for planning purposes. For formal transactions, engage a life sciences-focused financial advisor.
As featured in
Run your Biotech valuation
Get a valuation range with the methods behind it and a PDF memorandum in under 10 minutes.
Related industries
Biotech & Pharma
Value a drug developer program by program, each at its own chance of approval, from the pitch deck, the company's pipeline page or a US ticker.
Healthcare Devices
Value a medical device company on its products, each forecast at its own odds of reaching the market, with the cap table, the next round and the runway it buys.
Medical Labs
Value a clinical or diagnostic lab on its test volume and the net reimbursement it collects per test, with fee-schedule pressure and operating leverage read as buyers do.
Healthcare Services
Value a healthcare services company on normalized EBITDA, with the multiple chosen from the payer mix: commercial insurers pay more than government plans.